Literature DB >> 2633878

Glucose-6-phosphate dehydrogenase deficiency. WHO Working Group.

.   

Abstract

Glucose-6-phosphate dehydrogenase (G6PD) deficiency is the commonest enzyme disorder of human beings and a globally important cause of neonatal jaundice, which can lead to kernicterus and death or spastic cerebral palsy. It can also lead to life-threatening haemolytic crises in childhood and at later ages, by interacting with specific drugs and with fava beans in the diet. The complications of G6PD deficiency can largely be prevented by education and information, and neonatal jaundice can be successfully treated by phototherapy, a cheap and simple approach suitable for use in primary health care. This update describes developments in the methodology for characterizing G6PD deficiency, recent knowledge of the factors that can cause haemolysis, community approaches for prevention of haemolytic crises and neonatal jaundice, and the implications of recent advances at the DNA level.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2633878      PMCID: PMC2491315     

Source DB:  PubMed          Journal:  Bull World Health Organ        ISSN: 0042-9686            Impact factor:   9.408


  4 in total

1.  Interaction between the glucose-6-phosphate dehydrogenase deficiency and thalassaemia genes at phenotype level.

Authors:  G Sanna; F Frau; M A Melis; R Galanello; S De Virgiliis; A Cao
Journal:  Br J Haematol       Date:  1980-04       Impact factor: 6.998

2.  Adaptation of Plasmodium falciparum to glucose 6-phosphate dehydrogenase-deficient host red cells by production of parasite-encoded enzyme.

Authors:  E A Usanga; L Luzzatto
Journal:  Nature       Date:  1985 Feb 28-Mar 6       Impact factor: 49.962

3.  Favism and hemolytic anemia in glucose-6-phosphate dehydrogenase-deficient subjects in North Sardinia.

Authors:  T Meloni; G Forteleoni; A Dore; S Cutillo
Journal:  Acta Haematol       Date:  1983       Impact factor: 2.195

4.  Phototherapy for neonatal jaundice in erythrocyte glucose-6-phosphate dehydrogenase-deficient infants.

Authors:  K L Tan
Journal:  Pediatrics       Date:  1977-06       Impact factor: 7.124

  4 in total
  186 in total

Review 1.  Review: Improving the therapeutic index of 8-aminoquinolines by the use of drug combinations: review of the literature and proposal for future investigations.

Authors:  Hla Y Myint; Jonathan Berman; Larry Walker; Brandon Pybus; Victor Melendez; J Kevin Baird; Colin Ohrt
Journal:  Am J Trop Med Hyg       Date:  2011-12       Impact factor: 2.345

2.  Assessment of G6PD screening program in premature infants in a NICU.

Authors:  R Lam; H Li; M L Nock
Journal:  J Perinatol       Date:  2015-10-22       Impact factor: 2.521

3.  Prevalence and Genetic Characterization of Glucose-6-Phosphate Dehydrogenase Deficiency in Anemic Subjects from Uttar Pradesh, India.

Authors:  Poonam Tripathi; Sarita Agarwal; Srinivasan Muthuswamy
Journal:  J Pediatr Genet       Date:  2019-01-30

Review 4.  8-Aminoquinoline Therapy for Latent Malaria.

Authors:  J Kevin Baird
Journal:  Clin Microbiol Rev       Date:  2019-07-31       Impact factor: 26.132

5.  Newborn Screening for Congenital Hypothyroidism, Congenital Adrenal Hyperplasia, and Glucose-6-Phosphate Dehydrogenase Deficiency for Improving Health Care in India.

Authors:  Jyotsna Verma; Papai Roy; Divya C Thomas; Geetu Jhingan; Azad Singh; Sunita Bijarnia-Mahay; Ishwar C Verma
Journal:  J Pediatr Intensive Care       Date:  2019-10-14

6.  Neonatal anemia associated with Southeast Asian ovalocytosis.

Authors:  Vichai Laosombat; Supaporn Dissaneevate; Malai Wongchanchailert; Benjamas Satayasevanaa
Journal:  Int J Hematol       Date:  2005-10       Impact factor: 2.490

Review 7.  Prevention of Kernicterus in South Asia: role of neonatal G6PD deficiency and its identification.

Authors:  Yassar H Arain; Vinod K Bhutani
Journal:  Indian J Pediatr       Date:  2014-04-26       Impact factor: 1.967

8.  Randomized, double-blind, placebo-controlled clinical trial of a two-day regimen of dihydroartemisinin-piperaquine for malaria prevention halted for concern over prolonged corrected QT interval.

Authors:  Jessica Manning; Pattaraporn Vanachayangkul; Chanthap Lon; Michele Spring; Mary So; Darapiseth Sea; Youry Se; Sok Somethy; Sut-Thang Phann; Soklyda Chann; Sabaithip Sriwichai; Nillawan Buathong; Worachet Kuntawunginn; Mashamon Mitprasat; Raveewan Siripokasupkul; Paktiya Teja-Isavadharm; Eugene Soh; Ans Timmermans; Charlotte Lanteri; Jaranit Kaewkungwal; Montida Auayporn; Douglas Tang; Char Meng Chour; Satharath Prom; Mark Haigney; Louis Cantilena; David Saunders
Journal:  Antimicrob Agents Chemother       Date:  2014-08-04       Impact factor: 5.191

9.  Performance of the CareStart glucose-6-phosphate dehydrogenase (G6PD) rapid diagnostic test in Gressier, Haiti.

Authors:  Michael E von Fricken; Thomas A Weppelmann; Will T Eaton; Roseline Masse; Madsen V E Beau de Rochars; Bernard A Okech
Journal:  Am J Trop Med Hyg       Date:  2014-04-28       Impact factor: 2.345

Review 10.  Impact of glucose-6-phosphate dehydrogenase deficiency on the pathophysiology of cardiovascular disease.

Authors:  Peter A Hecker; Jane A Leopold; Sachin A Gupte; Fabio A Recchia; William C Stanley
Journal:  Am J Physiol Heart Circ Physiol       Date:  2012-12-15       Impact factor: 4.733

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.